$15.650
-0.294 (-1.88%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de RARE por análisis de gráficos similares
Alphio's RARE stock price prediction model matches the current Ultragenyx Pharmaceutical Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $15.60 (-0.34%). The 1-week path is $15.57 (-0.49%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de Ultragenyx Pharmaceutical Inc?
Ultragenyx Pharmaceutical Inc (RARE) is a good buy right now due to its recent FDA approval of Fayuvi, which is expected to drive revenue growth and has led analysts to raise price targets significantly. The current price is $15.65, with a price target from Cantor Fitzgerald at $39, suggesting a potential upside of 166%. Additionally, the company recently sold a Priority Review Voucher for $210 million, providing substantial non-dilutive capital to support its drug development pipeline. However, the main risk is the company’s ongoing negative net income, which was reported at -$92 million in Q2 2026, indicating that while there are positive catalysts, the company still faces financial challenges that could impact its performance.
RARE cerró en $15.65 el Friday, tras bajar -1.88%
Ultragenyx Pharmaceutical Inc (RARE) last closed at $15.65, losing -1.88%. These facts feed the 1-day and 1-week RARE price prediction above.
Consenso de analistas
Ultragenyx Pharmaceutical Inc (RARE): 10 comprar, 7 mantener, 1 vender. Perspectiva: Buy.
Sell / Buy
Technical signals summary based on buy and sell indicators. The gauge shows the overall market view.
Factores de la previsión
Los factores de la previsión de Ultragenyx Pharmaceutical Inc (RARE) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de RARE, ordenadas por similitud.
Análisis de estacionalidad de RARE
Historically the probability of a positive October return for RARE is 36.51%. August offers the highest probability of a positive month at 65.62%, while December is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Proyecciones de precio a 10 años de RARE
| Mes | Precio mínimo | Precio medio | Precio máximo | ROI potencial |
|---|---|---|---|---|
| Oct 2026 | $43.78 | $51.74 | $56.68 | +230.61% |
| Nov 2026 | $50.96 | $51.74 | $51.97 | +230.61% |
| Dec 2026 | $49.40 | $49.73 | $52.29 | +217.78% |
En 2026, se proyecta que Ultragenyx Pharmaceutical Inc (RARE) oscile entre $43.78 y $56.68.
Previsión mensual de Ultragenyx Pharmaceutical Inc para 2026
En Oct de 2026, se proyecta que Ultragenyx Pharmaceutical Inc promedie $51.74, con un mínimo de $43.78 y un máximo de $56.68.
En Nov de 2026, se proyecta que Ultragenyx Pharmaceutical Inc promedie $51.74, con un mínimo de $50.96 y un máximo de $51.97.
En Dec de 2026, se proyecta que Ultragenyx Pharmaceutical Inc promedie $49.73, con un mínimo de $49.40 y un máximo de $52.29.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.